BHC
Bausch Health Companies Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$2.11B
5Y Perf.-41.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BHC vs BLCO
Revenue, margins, valuation, and 5-year total return — side by side.
BLCO
Bausch + Lomb Corporation
Medical - Instruments & Supplies
Market Cap$5.70B
5Y Perf.-5.9%
BHC vs BLCO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BHC | BLCO |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Instruments & Supplies |
| Market Cap | $2.11B | $5.70B |
| Revenue (TTM) | $10.55B | $5.21B |
| Net Income (TTM) | $-1.19B | $-219M |
| Gross Margin | 61.7% | 55.9% |
| Operating Margin | 22.9% | 5.9% |
| Forward P/E | 1.3x | 20.2x |
| Total Debt | $21.21B | $5.37B |
| Cash & Equiv. | $1.32B | $383M |
BHC vs BLCO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BHC
BLCO
| Stock | May 22 | May 26 | Return |
|---|---|---|---|
| Bausch Health Compa… (BHC) | 100 | 58.1 | -41.9% |
| Bausch + Lomb Corpo… (BLCO) | 100 | 94.1 | -5.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BHC vs BLCO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BHC and BLCO are tied at the top with 3 categories each — the right choice depends on your priorities. Bausch + Lomb Corporation is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
BHC
Bausch Health Companies Inc.
The Income Pick
BHC has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.
- Dividend streak 2 yrs, beta 1.02
- Rev growth 8.5%, EPS growth 430.8%, 3Y rev CAGR 8.7%
- Lower volatility, beta 1.02, current ratio 1.47x
Best for: income & stability and growth exposure
BLCO
Bausch + Lomb Corporation
The Long-Run Compounder
BLCO is the clearest fit if your priority is long-term compounding.
- -20.0% 10Y total return vs BHC's -81.1%
- -4.2% margin vs BHC's -11.3%
- +46.8% vs BHC's +19.2%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BHC | 8.5% revenue growth vs BLCO's 6.5% |
| Value | BHC | Lower P/E (1.3x vs 20.2x) |
| Quality / Margins | BLCO | -4.2% margin vs BHC's -11.3% |
| Stability / Safety | BHC | Beta 1.02 vs BLCO's 1.39 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | BLCO | +46.8% vs BHC's +19.2% |
| Efficiency (ROA) | BLCO | -1.6% ROA vs BHC's -4.5%, ROIC 1.2% vs 8.2% |
BHC vs BLCO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
BHC vs BLCO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBHCLAGGINGBLCO
BLCOBausch + Lomb Corpora…
1leads
BHCBausch Health Compani…
3leads
6 Total Categories
CATEGORYLEADERvs BLCOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BHC4/6
Valuation MetricsMultiples, price ratios, and targets
BHC3/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BHC5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
BLCO4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BHC leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BHC is the larger business by revenue, generating $10.6B annually — 2.0x BLCO's $5.2B. BLCO is the more profitable business, keeping -4.2% of every revenue dollar as net income compared to BHC's -11.3%.
| Metric | BHCBausch Health Com… | BLCOBausch + Lomb Cor… |
|---|---|---|
| RevenueTrailing 12 months | $10.6B | $5.2B |
| EBITDAEarnings before interest/tax | $3.6B | $724M |
| Net IncomeAfter-tax profit | -$1.2B | -$219M |
| Free Cash FlowCash after capex | $990M | $4M |
| Gross MarginGross profit ÷ Revenue | +61.7% | +55.9% |
| Operating MarginEBIT ÷ Revenue | +22.9% | +5.9% |
| Net MarginNet income ÷ Revenue | -11.3% | -4.2% |
| FCF MarginFCF ÷ Revenue | +9.4% | +0.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +10.5% | +9.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -22.7% | +66.7% |
BHC leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
BHC leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, BHC's 6.4x EV/EBITDA is more attractive than BLCO's 17.6x.
| Metric | BHCBausch Health Com… | BLCOBausch + Lomb Cor… |
|---|---|---|
| Market CapShares × price | $2.1B | $5.7B |
| Enterprise ValueMkt cap + debt − cash | $22.0B | $10.7B |
| Trailing P/EPrice ÷ TTM EPS | 13.14x | -15.69x |
| Forward P/EPrice ÷ next-FY EPS est. | 1.31x | 20.23x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 6.37x | 17.56x |
| Price / SalesMarket cap ÷ Revenue | 0.20x | 1.12x |
| Price / BookPrice ÷ Book value/share | 5.63x | 0.87x |
| Price / FCFMarket cap ÷ FCF | 2.10x | — |
BHC leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
BHC leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
BHC delivers a 5.9% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-3 for BLCO. BLCO carries lower financial leverage with a 0.82x debt-to-equity ratio, signaling a more conservative balance sheet compared to BHC's 56.36x. On the Piotroski fundamental quality scale (0–9), BHC scores 7/9 vs BLCO's 3/9, reflecting strong financial health.
| Metric | BHCBausch Health Com… | BLCOBausch + Lomb Cor… |
|---|---|---|
| ROE (TTM)Return on equity | +5.9% | -3.4% |
| ROA (TTM)Return on assets | -4.5% | -1.6% |
| ROICReturn on invested capital | +8.2% | +1.2% |
| ROCEReturn on capital employed | +10.6% | +1.6% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 3 |
| Debt / EquityFinancial leverage | 56.36x | 0.82x |
| Net DebtTotal debt minus cash | $19.9B | $5.0B |
| Cash & Equiv.Liquid assets | $1.3B | $383M |
| Total DebtShort + long-term debt | $21.2B | $5.4B |
| Interest CoverageEBIT ÷ Interest expense | 1.43x | 0.71x |
BHC leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
BLCO leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BLCO five years ago would be worth $8,000 today (with dividends reinvested), compared to $2,035 for BHC. Over the past 12 months, BLCO leads with a +46.8% total return vs BHC's +19.2%. The 3-year compound annual growth rate (CAGR) favors BHC at -1.9% vs BLCO's -4.3% — a key indicator of consistent wealth creation.
| Metric | BHCBausch Health Com… | BLCOBausch + Lomb Cor… |
|---|---|---|
| YTD ReturnYear-to-date | -21.6% | -3.5% |
| 1-Year ReturnPast 12 months | +19.2% | +46.8% |
| 3-Year ReturnCumulative with dividends | -5.7% | -12.5% |
| 5-Year ReturnCumulative with dividends | -79.6% | -20.0% |
| 10-Year ReturnCumulative with dividends | -81.1% | -20.0% |
| CAGR (3Y)Annualised 3-year return | -1.9% | -4.3% |
BLCO leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BHC and BLCO each lead in 1 of 2 comparable metrics.
Risk & Volatility
BHC is the less volatile stock with a 1.02 beta — it tends to amplify market swings less than BLCO's 1.39 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BLCO currently trades 84.6% from its 52-week high vs BHC's 65.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BHCBausch Health Com… | BLCOBausch + Lomb Cor… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.02x | 1.39x |
| 52-Week HighHighest price in past year | $8.69 | $18.92 |
| 52-Week LowLowest price in past year | $4.41 | $10.83 |
| % of 52W HighCurrent price vs 52-week peak | +65.0% | +84.6% |
| RSI (14)Momentum oscillator 0–100 | 52.0 | 46.9 |
| Avg Volume (50D)Average daily shares traded | 1.8M | 416K |
Evenly matched — BHC and BLCO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates BHC as "Buy" and BLCO as "Hold". Consensus price targets imply 41.6% upside for BHC (target: $8) vs 18.8% for BLCO (target: $19).
| Metric | BHCBausch Health Com… | BLCOBausch + Lomb Cor… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $8.00 | $19.00 |
| # AnalystsCovering analysts | 38 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 2 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
BHC leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). BLCO leads in 1 (Total Returns). 1 tied.
Best OverallBausch Health Companies Inc. (BHC)Leads 3 of 6 categories
Loading custom metrics...
BHC vs BLCO: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is BHC or BLCO a better buy right now?
For growth investors, Bausch Health Companies Inc.
(BHC) is the stronger pick with 8. 5% revenue growth year-over-year, versus 6. 5% for Bausch + Lomb Corporation (BLCO). Bausch Health Companies Inc. (BHC) offers the better valuation at 13. 1x trailing P/E (1. 3x forward), making it the more compelling value choice. Analysts rate Bausch Health Companies Inc. (BHC) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BHC or BLCO?
On forward P/E, Bausch Health Companies Inc.
is actually cheaper at 1. 3x.
03Which is the better long-term investment — BHC or BLCO?
Over the past 5 years, Bausch + Lomb Corporation (BLCO) delivered a total return of -20.
0%, compared to -79. 6% for Bausch Health Companies Inc. (BHC). Over 10 years, the gap is even starker: BLCO returned -20. 0% versus BHC's -81. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BHC or BLCO?
By beta (market sensitivity over 5 years), Bausch Health Companies Inc.
(BHC) is the lower-risk stock at 1. 02β versus Bausch + Lomb Corporation's 1. 39β — meaning BLCO is approximately 37% more volatile than BHC relative to the S&P 500. On balance sheet safety, Bausch + Lomb Corporation (BLCO) carries a lower debt/equity ratio of 82% versus 56% for Bausch Health Companies Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — BHC or BLCO?
By revenue growth (latest reported year), Bausch Health Companies Inc.
(BHC) is pulling ahead at 8. 5% versus 6. 5% for Bausch + Lomb Corporation (BLCO). On earnings-per-share growth, the picture is similar: Bausch Health Companies Inc. grew EPS 430. 8% year-over-year, compared to -13. 3% for Bausch + Lomb Corporation. Over a 3-year CAGR, BLCO leads at 10. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BHC or BLCO?
Bausch Health Companies Inc.
(BHC) is the more profitable company, earning 1. 5% net margin versus -7. 1% for Bausch + Lomb Corporation — meaning it keeps 1. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BHC leads at 21. 3% versus 3. 7% for BLCO. At the gross margin level — before operating expenses — BHC leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BHC or BLCO more undervalued right now?
On forward earnings alone, Bausch Health Companies Inc.
(BHC) trades at 1. 3x forward P/E versus 20. 2x for Bausch + Lomb Corporation — 18. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BHC: 41. 6% to $8. 00.
08Which pays a better dividend — BHC or BLCO?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is BHC or BLCO better for a retirement portfolio?
For long-horizon retirement investors, Bausch Health Companies Inc.
(BHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 02)). Both have compounded well over 10 years (BHC: -81. 1%, BLCO: -20. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BHC and BLCO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BHC is a small-cap deep-value stock; BLCO is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(BHC: 10.5% · BLCO: 9.4%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.